Trinity Capital

TRIN

Market cap $1.12B

BDC earnings are sensitive to interest rates. As there is no meaningful margin of safety in the BDC system, forthcoming interest rate cuts might trigger a wave of dividend cuts. For prudent passive income investors who want to avoid experiencing stress that is associated with dividend reductions, BDCs might not seem like a good option.

Hercules Capital and Trinity Capital are best positioned among BDCs to sustain base dividends amid possible lower interest rates. Both HTGC and TRIN benefit from strong fundamentals, investment-grade credit ratings, robust liquidity, and internally managed structures, supporting dividend stability. Contractual interest rate floors and NAV premiums provide HTGC and TRIN with defensive advantages over peers facing greater earnings declines from rate cuts.

This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LYB, with analysts forecasting 30.84% to 70.61% upside by October 2026. Nine of the top ten ReFa/Ro Dogs meet the 'ideal' criterion: dividends from $1,000 invested exceed their share price, emphasizing value and income.

The Fed's dovishness has been the key driver for the BDC sell-off. The idea is that lower interest rates should lead to lower dividends (i.e., BDCs cutting their dividend across the board). While it is a process that takes time, the current data show that many BDCs are well-positioned to safeguard their existing dividends.

Of 35 November Dividend Power Dogs, 12 are recommended for "safer" dividends, with free-cash-flow-yields exceeding dividend-yields, and returns from $1,000 invested equaling-or-exceeding share-price, making them ideal buys. Analyst forecasts project average net gains of 36.78% for the top ten DiviPower stocks by November 2026, with strong upside potential in select financials. Caution is advised for stocks with negative free cash flow margins, as 18 of 35 are considered cash-poor and riskier for dividend sustainability.

The Undercovered Dozen highlights 12 lesser-followed stocks and ETFs, offering fresh investment ideas and sparking community discussion on Seeking Alpha. This week's edition covers articles published between Nov. 7 and Nov. 13, offering fresh investment ideas. Ratings range from strong buy (ACHR, VICI, PSEC) to hold (JEPQ, MSTY) and sell (EOSE, VGT, XLK), with detailed justifications based on valuation, yield, and growth prospects.

BDCs have had a rough year so far. Yet, Q3 earnings data points indicate that the tide could be turning. While there are some tangible improvements in BDC business environment, many risks remain open.

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized                                                         Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026 Announced encouraging updated survival data for patients enrolled in its phase 1b clinical trial of CAN-3110 (linoserpaturev) in recurrent high-grade glioma (rHGG) Manuscript published in the scientific journal Science Translational Medicine, reporting the tissue response to CAN-3110 based on the analysis of serial tumor biopsies from two patients treated with multiple administrations of CAN-3110 in arm C of the phase 1b clinical trial Plan to submit a Biologics License Application (BLA) for CAN-2409 in intermediate-to-high-risk localized prostate cancer in Q4 2026 Entered into a $130 million term loan facility with Trinity Capital Inc. for a $50 million drawn down at closing, with access to up to an additional $80 million Cash and cash equivalents of $87.0M, as of September 30, 2025, plus the upfront proceeds from the Trinity Capital debt facility, strengthens the Company's financial position to fund initiation of potentially registrational phase 3 trial of CAN-2409 in NSCLC and other planned operations into Q1 2027 NEEDHAM, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the third quarter ended September 30, 2025, and provided a corporate update.

Trinity Capital has dipped by just over 11% from its near-term peak, expanding its fully covered dividend yield to 14%. The BDC is pushing ahead with portfolio growth, with its total debt investments at cost valued at $2.03 billion at the end of the third quarter, up 8.5% sequentially. NII downside from Fed rate cuts will be limited, due to a majority of loans being embedded with interest rate floors, and with 40.6% of TRIN's outstanding borrowing at a floating rate.

The market did not react well when TRIN issued its Q3 report. In my view, the reasons for the correction confirm yet again that the market is extremely short-term oriented. In reality, TRIN's performance was strong across the board, sending the exact messages that long-term and durable yield investors want to hear.